JohnFTisdaleMD

Internal Medicine • Bethesda, MD

Hematology/Oncology

Senior Investigator/National Institutes of Health

Join to view full profile

Dr. Tisdale is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tisdale's full profile

Already have an account?

Office
8600 Old Georgetown Rd
Bethesda, MD 20814
Phone+1 301-896-3517

Fax+1 301-493-4259

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1994 - 1996
Vanderbilt University Medical CenterResidency, Internal Medicine, 1990 - 1994
Medical University of South CarolinaClass of 1990

Certifications & Licensure

MD State Medical License 2004 - 2025

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 2010

Clinical Trials

Collection and Storage of Umbilical Cord Stem Cells for Treatment of Sickle Cell Disease Start of enrollment: 2001 Nov 01
Recruiting
Stem Cell Collection for Adult Volunteers Start of enrollment: 2002 Apr 29
Terminated
Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia Start of enrollment: 2003 Mar 10
Completed
Phase 1
Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias Start of enrollment: 2004 Jul 16
Active, not recruiting
Phase 1, Phase 2
Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease Start of enrollment: 2003 Nov 04
Completed
Phase 1
Natural History of Sickle Cell Disease Start of enrollment: 2004 Apr 29
Recruiting
Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease Start of enrollment: 2004 Nov 01
Completed
Phase 1
Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia Start of enrollment: 2005 Dec 21
Completed
Phase 1
Niacin to Improve Blood Flow in People With Sickle Cell Disease Start of enrollment: 2007 Jul 24
Completed
Phase 2
Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease Start of enrollment: 2021 Apr 19
Completed
Early Phase 1
Roles: Contact, Principal Investigator
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia Start of enrollment: 2022 May 12
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling Start of enrollment: 2024 May 17
Recruiting
Early Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells.
Jing Zeng, My Anh Nguyen, Pengpeng Liu, Lucas Ferreira da Silva, Sébastien Levesque
Cell Stem Cell. 2024-12-11
BCL11A +58/+55 enhancer-editing facilitates HSPC engraftment and HbF induction in rhesus macaques conditioned with a CD45 antibody-drug conjugate.
Selami Demirci, Jing Zeng, Rahul Palchaudhuri, Chuanfeng Wu, Diana M Abraham
Cell Stem Cell. 2024-12-05
1 citations
Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34cell therapy to induce fetal hemoglobin for sickle cell disease.
Varun Katta, Kiera O'Keefe, Yichao Li, Thiyagaraj Mayuranathan, Cicera R Lazzarotto
Molecular Therapy. 2024-10-02

Journal Articles

Transfusion Support for Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation (1993–2010): Factors That Predict Intensity and Time to Transfusion Independ...
Richard W Childs, John F Tisdale, Transfusion

Abstracts/Posters

The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy
John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy
John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safe and Efficient Peripheral Blood Stem Cell Collection in Patients with Sickle Cell Disease Using Plerixafor
John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Zinc Finger Nuclease-Mediated Disruption of the BCL11A Erythroid Enhancer Results in Enriched Biallelic Editing, Increased Fetal Hemoglobin, and Reduced Sickling in Er...
John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study
John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preclinical Evaluation for Engraftment of Gene-Edited CD34+ Cells with a Sickle Cell Disease Mutation in a Rhesus Transplantation Model
John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Durable and Robust Fetal Globin Induction without Anemia in Rhesus Monkeys Following Autologous Hematopoietic Stem Cell Transplant with BCL11A Erythroid Enhancer Editing
John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CRISPR-Cas9 Genome Editing of _-Globin Promoters in Human Hematopoietic Stem Cells to Induce Erythrocyte Fetal Hemoglobin for Treatment of _-Hemoglobinopathies
John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease
60th American Society of Hematology Annual Meeting - 12/2/2018
Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease
60th American Society of Hematology Annual Meeting - 12/1/2018
Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Development of a Clinically Applicable Method for High-Efficiency Gene Correction of Plerixafor-Mobilized CD34+ Cells from Patients with Sickle Cell Disease
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta ThalassemiaJanuary 3rd, 2023
Health News | Experimental Gene Therapy Reverses Sickle Cell Disease for Years: StudyJanuary 1st, 2022
Study Finds Experimental Gene Therapy Reverses Sickle Cell Disease for YearsDecember 27th, 2021
Join now to see all

Grant Support

14C As A Marker For Beta Cell Turnover In Adult HumansNational Center For Research Resources2011
Nonmyeloablative Allogeneic PBSC In Globin DisordersNational Heart, Lung, And Blood Institute2009–2011
Isolation, Characterization, And Transplantation Of Candidate Stem CellsNational Heart, Lung, And Blood Institute2009–2011
A Preclinical Large Animal Model For Globin Gene TransferNational Heart, Lung, And Blood Institute2009–2011
Development Of Improved Lentiviral Vectors For Human Gene Therapy ApplicationsNational Heart, Lung, And Blood Institute2009
Development Of Improved Lentiviral Vectors For Human Gene Therapy ApplicationsNational Heart, Lung, And Blood Institute2008
Isolation, Characterization, And Transplantation Of Candidate Stem CellsNational Institute Of Diabetes And Digestive And Kidney Diseases2007
A Preclinical Large Animal Model For Globin Gene TransferNational Institute Of Diabetes And Digestive And Kidney Diseases2007
Nonmyeloablative Allogeneic PBSC In Globin DisordersNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2007
Isolation, Characterization, And Transplantation Of CandNational Institute Of Diabetes And Digestive And Kidney Diseases2006
A Preclinical Large Animal Model For Globin Gene TransfeNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2006
Isolation, Characterization, And Transplantation Of StemNational Institute Of Diabetes And Digestive And Kidney Diseases2005